# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

> **NCT02173665** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1356 BS - Powder in bottle (PIB)
- **DRUG:** BI 1356 BS - Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02173665
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173665, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02173665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*